Lars Fruergaard Jørgensen, Novo Nordisk CEO (EUBIO21)
Novo Nordisk to make all doses of its weight loss drug available in the US by end of the year
With production finally up and running for its weight loss drug Wegovy, Novo Nordisk said on Wednesday that it plans to make all dose strengths available in the US by the end of the year.
However, CEO Lars Fruergaard Jørgensen also noted “a bit lower ramp-up versus planned,” as the company’s stock $NVO plummeted more than 12% on Wednesday. Shares were back up 4.6% on Thursday, pricing in at around $104.54 apiece.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
